Leukemia & Other Blood Cancers
Leukemia is a type of cancer that affects the blood and bone marrow, the spongy center of bones where blood cells are formed. The disease develops when blood cells produced in the bone marrow grow out of control. The four most common types of leukemia are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
Acute myeloid leukemia is a type of bone marrow cancer. The American Cancer Society estimates that more than 14,500 cases of AML will be diagnosed in the United States during 2013, and more than 10,000 people will die from the disease.
Acute lymphoblastic leukemia (also called acute lymphocytic leukemia) is a type of blood and bone marrow cancer. The American Cancer Society estimates that more than 6,000 new cases of ALL will be diagnosed in the United States during 2013, and more than 1,400 people will die from the disease.
Multiple myeloma is cancer that starts in the plasma cells in bone marrow. The American Cancer Society estimates that more than 22,000 new cases of multiple myeloma will be diagnosed in the United Statins during 2013, and nearly 11,000 will die from the disease.
Leukemia & Other Blood Cancer Clinical Trials
Brentuximab vedotin phase 2 trial for CD30-positive non-lymphoma malignancies
Single-agent trial assessing the antitumor activity and safety as well as the relationship of CD30 expression with antitumor activity of brentuximab vedotin in patients with CD30-positive non-lymphoma malignancies, including acute lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, and a number of solid tumors who have failed, refused or have been deemed ineligible for standard therapy. Study #SGN35-013
SGN-CD19A phase 1 trial for B-lineage acute lymphoblastic leukemia and highly aggressive lymphomas
Open-label trial evaluating the safety, tolerability and antitumor activity of SGN-CD19A in B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL) and highly aggressive lymphomas. Study #SGN19A-0001
SGN-CD33A phase 1 trial for acute myeloid leukemia (AML)
Trial to evaluate the safety, tolerability and antitumor activity of SGN-CD33A as a single agent in patients with acute myeloid leukemia. Study #SGN33A-001